<DOC>
	<DOC>NCT00219167</DOC>
	<brief_summary>After a wash-out (1 to 2 weeks), and 2 to 4 week single-blind placebo run-in period, eligible patients will be randomized to receive lisinopril 10 mg, aliskiren 75 mg, 150 mg or 300 mg for a period of 8 weeks</brief_summary>
	<brief_title>A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Inclusion Criteria Patients with at least 65 yearsold Patients with essential hypertension Exclusion Criteria Severe hypertension History or evidence of a secondary form of hypertension History of Hypertensive encephalopathy or cerebrovascular accident. Other protocoldefined inclusion exclusion criteria also apply.</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>hypertension</keyword>
	<keyword>aliskiren</keyword>
	<keyword>age</keyword>
</DOC>